At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 49 enrolled
Drug / intervention
liraglutide +2 moredrug
Likely dose
glimepiride 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus: A 12-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial With an Open-label Glimepiride Arm
In Brief
A Phase 3 clinical trial evaluating liraglutide, placebo, and 1 other intervention for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 49 participants across 1 site.
Detailed Summary
This trial is conducted in the United States of America (USA). The purpose of the trial is to assess the effect of liraglutide on forearm blood flow in subjects with type 2 diabetes who are on diet and lifestyle changes or treated with metformin alone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2008
First PostedFeb 2008
Primary CompletionMay 2010
TodayJul 2026
First PostedFeb 21, 2008
Enrollment StartFeb 1, 2008
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.4 years ago
Interventions
liraglutidedrug
Stepwise dose increase, s.c. (under the skin) injection, once daily
placebodrug
Liraglutide placebo, stepwise dose increase, s.c. (under the skin) injection, once daily
glimepiridedrug
Tablets, 1 - 4 mg daily